Market Assessment, Multiple Sclerosis Current Treatment EU5 2016 Report

The EU5 market for multiple sclerosis (MS) disease-modifying therapies (DMTs) is dynamic and evolving. More than ten key branded DMTs are available, with several launching in the past five years, each delivering a unique balance of benefit, risk, and convenience. New agents, in particular oral DMTs, have meaningfully altered physician preferences and introduced new complexity into an already complicated treatment paradigm. Understanding the many decision points facing EU5 neurologists in the shifting treatment of MS provides, and in five unique countries, important context for developers of marketed and pipeline DMTs.

Back to all Market Assessment reports

Contact us

Investors

Careers

Login

Multiple Sclerosis | Current Treatment | EU5 | 2016

Related Market Assessment Reports

Myasthenia Gravis – Current Treatment – Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis (US)

Urticaria – Current Treatment – Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis – Chronic Inducible Urticaria (US) 2023

Ulcerative Colitis – Current Treatment – Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis – Adult (US)

Pulmonary Hypertension – Current Treatment – Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis (US)

Multiple Sclerosis – Landscape & Forecast – Disease Landscape & Forecast